|Bid||14.72 x 1000|
|Ask||16.36 x 1100|
|Day's Range||14.58 - 15.42|
|52 Week Range||10.30 - 27.00|
|Beta (3Y Monthly)||2.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Omeros announced Thursday ahead of the market open that it has reached an agreement with the FDA on the response-based primary endpoint of its pivotal trial to support the biologic license application for narsoplimab. Narosoplimab, codenamed OMS721, is Omeros' lead human monoclonal antibody candidate for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA. Omeros said it will now complete the ongoing data collection from medical records of patients already treated with narosplimab either in the clinical trial or under compassionate use for inclusion in the clinical sections of the BLA.
In 1994 Gregory Demopulos was appointed CEO of Omeros Corporation (NASDAQ:OMER). First, this article will compare CEO...
Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Seattle-based company said it had a loss of 50 cents per share. Losses, adjusted for non-recurring costs, came to 38 cents per share. The drug developer posted revenue of $21.8 million in the period. ...
Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
IgA nephropathy is a kidney disease resulting from the accumulation of an antibody called immunoglobin A in the kidney, which causes inflammation and in turn impacts the ability of the kidney to filter wastes from blood. Following a meeting with the FDA on the Phase 3 trial, Omeros said Thursday it has finalized its clinical plan for OMS721. The company said the FDA agreed to extend the primary endpoint of the assessment of proteinuria from 24 weeks to 36 weeks to allow additional dosing if warranted.
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Seattle-based company said it had a loss of 81 cents. Losses, adjusted for non-recurring costs, were 71 cents per share. The drug developer posted revenue of $4.6 million in the ...
Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.